Valneva and pfizer report six-month antibody persistence data in children and adults for lyme disease vaccine candidate

New york & saint- herblain (france) , december 1 , 2022 – pfizer inc. (nyse: pfe) and valneva se (nasdaq: valn; euronext paris: vla) today reported antibody persistence data six months after the completion of a three-dose (month 0-2-6) or a two-dose (month 0-6) vaccination schedule with their lyme disease vaccine candidate, vla15 in both children and adults. this is the first time antibody persistence data are reported in pediatric populations for this vaccine candidate.
VALN Ratings Summary
VALN Quant Ranking